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Introduction: The increasing interest in 99m-technetium (99mTc)-labeled stem cells encouraged us to study the
99mTc binding sites in stem cell compartments.
Methods: Bone marrow mononuclear cells were collected from femurs and tibia of rats. Cells were labeled with
99mTc by a direct method, in which reduced molecules react with 99mTc with the use of chelating agents, and lysed
carefully in an ultrasonic apparatus. The organelles were separated by means of differential centrifugation. At the
end of this procedure, supernatants and pellets were counted, and the percentages of radioactivity (in megabecquerels)
bound to the different cellular fractions were determined. Percentages were calculated by dividing the radioactivity in
each fraction by total radioactivity in the sample. The pellets were separated and characterized by their morphology on
electron microscopy.
Results: The labeling procedure did not affect viability of bone marrow mononuclear cells. Radioactivity distributions in
bone marrow mononuclear cell organelles, obtained in five independent experiments, were approximately 38.5 % in the
nuclei-rich fraction, 5.3 % in the mitochondria-rich fraction, 2.2 % in microsomes, and 54 % in the cytosol. Our results
showed that most of the radioactivity remained in the cytosol; therefore, this is an intracellular labeling procedure
that has ribosomes unbound to membrane and soluble molecules as targets. However, approximately 39 % of
the radioactivity remained bound to the nuclei-rich fraction. To confirm that cell disruption and organelle separation
were efficient, transmission electron microscopy assays of all pellets were performed.
Conclusions: Our results showed that most of the radioactivity was present in the cytosol fraction. More studies to
elucidate the mechanisms involved in the cellular uptake of 99mTc in bone marrow cells are ongoing.Introduction
Stem cells derived from different sources hold therapeutic
potential for the treatment of many diseases [1, 2]. Track-
ing these cells in vivo represents an ongoing challenge in
cell-based therapies [3, 4]. Advanced technology, such as
non-invasive imaging of transplanted cells to monitor
their fate in vivo, has been extensively used and may
provide important information for understanding the
mechanism of action of these therapies [5, 6].* Correspondence: bianca.gutfilen@gmail.com
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creativecommons.org/publicdomain/zero/1.0/Cell tracking for in vivo detection of grafted cells can be
performed by ultrasound, optical imaging, magnetic res-
onance imaging, micro-computed tomography imaging,
and nuclear medicine techniques [7, 8]. In general, the
ideal imaging modality is determined by the specificity,
sensitivity, resolution, and radiation exposure of individual
modalities [9].
All of the available imaging methods are based on
different principles, having different properties and limi-
tations. According to Frangioni and Hajjar [10], there
are eight characteristics of an ideal marker for stem cell
tracking: to be biocompatible, safe, and non-toxic; not to
produce genetic modification in the stem cell; to allow
quantification of exact cell number at any anatomic lo-
cation; to detect a small amount of cells; to be minimally
or not diluted by cell division; to be minimally or notticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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invasive imaging technology for months to years; and
not demand contrast agent injection. Although some
markers have many of these characteristics, none of
them fulfills all eight of the criteria presented above.
The fluorescent dyes are the most used to track injected
cells in pre-clinical trials. Among these fluorescent dyes,
the most commonly used are DAPI (4′6-diamidino-2-phe-
nylndole) and Hoechst 33342 (bis-benzimide). They
permeate through the plasma membrane and have strong
affinity to DNA, binding predominantly to the nucleus
[11, 12]. Another fluorescent dye widely used is Dil, a long
chain of carbocynine that, unlike DAPI and Hoechst,
binds to plasma membrane [13]. An advantage of labeling
cells with these dyes is to find the possible location and
integration of the cells to the tissue; however, these
markers are diluted with each cell division. Furthermore,
fluorescent dyes can be visualized only by microscopy,
which is not compatible with in vivo analysis.
More recently, bioluminescence imaging has been ex-
tensively used to detect the biodistribution of transplanted
cells in live small animals. The clinical application is re-
stricted since this technique is reporter gene-based [14].
Nuclear medicine is characterized by an excellent in vivo
sensitivity and whole-body imaging capabilities. This tech-
nique is suitable for tracking cells in both laboratory [15,
16] and clinical [17–20] settings. Radioisotope cell labeling
is a well-established method, and the most commonly used
radioisotopes are 111-indium or 99m-technetium (99mTc)
or 18F-fluorodeoxyglycose [18F]FDG [21].
The majority of stem cell clinical trials use bone mar-
row mononuclear cells (BMMCs), and 99mTc is the
radionuclide predominantly employed. Our research
group has successfully labeled stem cells with 99mTc. We
use a simple and efficient labeling technique that main-
tains cell viability and reaches high labeling efficiency
and stability rates [15, 17, 18, 20, 22, 23].
The increasing interest in 99mTc-labeled stem cells en-
couraged us to study the binding sites of 99mTc to stem
cell compartments. This study investigated the presence of
99mTc taken up by different organelles in BMMCs. Cells
were labeled with 99mTc by a direct method previously
described by our group [15, 24, 25]. The organelles were
separated by means of differential centrifugation and char-
acterized by their morphology on electron microscopy.Methods
Animals
All procedures were performed in accordance with the
Guide for Care and Use of Laboratory Animals (Department
of Health and Human Services Publication #NIH 85–23, re-
vised 1996; Office of Science and Health Reports, Bethesda,
MD, USA). This study was approved by the EthicsCommittee for Animal Use of the Federal University of Rio
de Janeiro under number IBCCF 028/2008.
Wistar rats were obtained from Instituto de Biof ísica
Carlos Chagas Filho (IBCCF) (Rio de Janeiro, Brazil). Ani-
mals were housed at a controlled temperature (23 °C) with
daily exposure to a 12:12 light-dark cycle.
Mononuclear cell isolation from bone marrow
Bone marrow cells obtained from Wistar rats were used
for cell labeling. Femurs and tibia were harvested, and all
adjacent muscle tissue was thoroughly removed. Bone
epiphysis was removed, and bone marrow was flushed by
using a syringe filled with Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco-Invitrogen, Carlsbad, CA,
USA). The cell suspension was carefully placed on top of
Ficoll Histopaque 1.083 (Sigma-Aldrich, St. Louis, MO,
USA) on 15 ml tubes maintaining a proportion of 1:1 in
volume. Tubes were centrifuged at 400×g for 30 min at
room temperature. Mononuclear cells were collected from
the interface formed between Ficoll Histopaque and
DMEM. Cells were washed in phosphate-buffered saline
(PBS) twice and counted in a hemocytometer, and viability
was checked by using trypan blue.
Labeling the cells with 99mTc
The BMMCs were labeled with 99mTcO4
− on the basis of
previously published protocols [15, 24, 25]. All the pro-
cedures for cell preparation and labeling were carried
out in a laminar flow. Briefly, 500 μl of fresh and sterile
SnCl2 (stannous chloride) solution was added to the cell
suspension in saline solution, and the mixture was incu-
bated at room temperature for 10 min. Then 45 MBq of
99mTcO4
− was added, and the incubation continued for
another 10 min. After centrifugation (500×g for 5 min),
the supernatant was removed, and the cells were washed
once more with NaCl 0.9 % solution. The pellet was
suspended in NaCl 0.9 % solution, and the viability of
the labeled cells was assessed by trypan blue exclusion
test. Labeling efficiency (percentage) was calculated by
the activity in the pellet divided by the sum of the radio-
activity in the pellet plus supernatant.
Differential centrifugation with lysed cells
After labeling and washing procedures, 1 ml of NaCl 0.9 %
solution was added, and the cells were carefully disrupted
on ice with 10 cycles of 2 sec, with 1 sec of rest between
cycles, in an ultrasonic apparatus (GEX 600 Model; Sigma-
Aldrich) by using a standard probe (13 mm radiating diam-
eter), operating at 10 % of total amplitude. Disruption
procedure was monitored by phase contrast microscopy,
and 0.5 ml of each homogenate sample was separated.
Cell homogenate was added to 10 ml of PBS and centri-
fuged (Beckman Optima™ Ultracentrifuge, model XL-100
K; Beckman Coulter, Pasadena, CA, USA, rotor 90 Ti) at
Fig. 1 Schematic diagram of differential centrifugation procedure applied to bone marrow mononuclear cells labeled with 99m-technetium (Tc-99m).
Percentages of radioactivity bound to each fraction are presented as mean ± standard deviation
Fig. 2 Distribution of 99m-technetium radioactivity in bone marrow
mononuclear subcellular fractions. Pellet I: nucleus, cells that were
not lysed, and large fragments of plasma membrane; pellet II: mainly
mitochondria, liposomes, and peroxisomes; pellet III: microsomal
fraction (endoplasmic reticulum and plasma membrane fragments);
supernatant III: cytoplasm, ribosomes unbound to membrane, and
soluble molecules
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reserved, and the supernatant was collected (supernatant
I) in a new centrifuge tube. A centrifugation of super-
natant I at 12,000×g for 20 min generated the second
pellet (pellet II) and supernatant (supernatant II). Pellet II
was reserved, and supernatant II was collected in a new
centrifuge tube. A third centrifugation at 100,000×g for 60
min resulted in pellet III and supernatant III [24, 26–28].
At the end of this procedure, supernatants and pellets
were counted in a well counter (PerkinElmer, Waltham,
MA, USA), and the percentages of radioactivity bound to
the different cellular fractions were determined.
Transmission electron microscopy
The three pellets were fixed with 2.5 % glutaraldehyde in
0.1 M sodium cacodylate buffer (pH 7.2). The superna-
tants were directly fixed by adding glutaraldehyde to the
final concentration of 2.5 %.
All samples were prepared for transmission electron mi-
croscopy on the basis of previously published protocols
[29]. In short, fixed samples were washed with saline solu-
tion, adopting the same centrifugation used to obtain the
fractions. Washed fractions were post-fixed in 1 % osmium
tetroxide, 0.8 % potassium ferrocyanide, and 5 mM calcium
chloride in 0.1 M cacodylate buffer (pH 7.2) for 60 min,
dehydrated in an acetone series, and embedded in Epoxy
resin. Ultrathin sections were stained with 5 % uranyl acet-
ate and lead citrate and observed in a Zeiss 900 transmis-
sion electron microscope (Carl Zeiss AG, Oberkochen,
Germany) operating at 80 kV.
Results
The viability of labeled cells was higher than 93 % in all
cases. The distribution of 99mTc radioactivity in BMMC
organelles is shown in Figs. 1 and 2. The labeling efficiency
results are presented as mean ± standard deviation of fiveindependent experiments. Most of the radioactivity
remained in the third supernatant (Figs. 1 and 2), which
contained the cytosol fraction formed by ribosomes
unbound to membrane and soluble molecules. However,
approximately 39 % of the radioactivity remained bound
to the first pellet, containing the nuclei-rich fraction.
To confirm that cell disruption and organelle separ-
ation were efficient, transmission electron microscopy
assays of all pellets were performed. Figure 3 shows
that the first pellet contained cells that were not lysed
(Fig. 3a) and nuclei and large cell fragments (Fig. 3b).
A B
C D
Fig. 3 Ultrathin sections of bone marrow mononuclear subcellular fractions observed under transmission electron microscope. Partially disrupted
cells (a) and large cell fragments (b) were found in pellet I, whereas mitochondria and lysosomes were the major component of pellet II (c). Many
membrane profiles were observed in pellet III (d). Bars correspond to 20 μm (a), 10 μm (b), and 1 μm (c and d)
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somes, and peroxisomes (Fig. 3c), and the third pellet
(Fig. 3d) was a typical microsomal fraction, constituted by
endoplasmic reticulum and plasma membrane fragments.
Discussion
When coupled to 99mTc, cells can be labeled with a rela-
tively inexpensive and widely available radionuclide. Many
studies show the feasibility of labeling stem cells with 99mTc
to track their homing [10, 15–21]. Usually, molecules such
as peptides and antibodies are labeled with 99mTc in order
to become probes to monitor cell migration.
There are many mechanisms of labeling molecules.
Essentially six major methods are employed in the prep-
aration of labeled compounds for clinical use. The ma-
jority of cell labeling methods use a chelating agent.
Here, we used a direct method of labeling with high cell
viability and stability rates [15, 17–20, 22–25].
Radionuclide cell labeling has already been applied for
tracking cells in cell therapy for myocardial infarction[30–32], cirrhosis [20], and acute stroke [18, 19, 33] in
humans. The 6-h half-life of 99mTc is an important
advantage over the half-life of 110 min of [18F]FDG.
111-Indium-oxine, another commonly used radiophar-
maceutical, allows cell tracking for up to 96 h but has
disadvantages that include suboptimal photon energies,
low-resolution images, and the requirement of an 18- to
24-h interval between injection and imaging [34, 35].
99mTc allows imaging for 24–48 h and results in higher
image resolution and a lower radiation burden to the
patient [34, 35].
Previous work by our group evaluated the binding sites
of 99mTc to mononuclear leukocytes since radiolabeled
leukocytes have a potential for clinical use in detecting
sites of inflammation [24]. In this work, we analyzed the
binding sites of 99mTc to BMMCs, which have a different
composition when compared with peripheral blood.
99mTc-labeled bone marrow mononuclear fraction has
been widely used in cell therapy experiments [17–20] with
the objective of tracking them after systemic infusion.
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electron microscopy data.
One of the most famous and most used radiopharma-
ceuticals to label leukocytes is 99mTc- hexamethylpropy-
leamine oxime (HMPAO). Some studies showed that
99mTc-HMPAO has high selectivity for eosinophils from
blood compared with neutrophils and other blood leuco-
cytes [26, 36]. In these cases, it was also shown that
99mTc-HMPAO is stored in the eosinophils mainly in
nuclear and cytoplasmic compartments.
As a crucial step to understanding the mechanism of
radiopharmaceutical localization in a specific target
organ for cell therapy, the interaction of the 99mTc with
bone marrow cells was evaluated. Our results showed
that this is an intracellular labeling procedure that has
cytoplasm, ribosomes unbound to membrane, and
soluble molecules as targets. However, the natural
interaction between 99mTc to the cytosolic substrate
still has to be elucidated.
Other radiopharmaceuticals, such as 99mTc-methoxyi-
sobutylisonitrile (MIBI) and 99mTc-dimercaptosuccinic
acid (DMSA), have had their binding sites studied be-
fore [27, 28, 37]. Similar to our results, data from whole
heart preparations, largely derived from differential centri-
fugation techniques, indicated that most of 99mTc-MIBI
appears to be associated with the cytosolic fraction. In this
study, especially designed to compare results of subcellular
fractionation obtained with 99mTc-(N-ethoxy,N-ethyl
dithiocarbamato) nitrido (N-NOEt) and 99mTc-MIBI,
interesting results emerged [37, 38]. The fact that 99mTc-
N-NOEt activity was not released into the cytosol after
membrane and organelle disruption suggested that this
lipophilic marker remained tightly bound to the hydro-
phobic components of the cells. On the other hand, the
monocationic 99mTc-MIBI complex, in the same situation,
was removed from disrupted mitochondria and trans-
ferred to the aqueous cytosolic phase. However, experi-
ments that use subcellular fractionation procedures
should be observed with caution because of dependence
of the results on two important parameters: time of
homogenization and centrifugation rates. In the men-
tioned study, if centrifugation time was extended to 180
sec, it was observed that approximately 70 % of 99mTc-
MIBI activity was released to cytosolic fraction as a result
of disruption of mitochondria [38]. This result is in agree-
ment with those reported by Crane et al. [37].
Subcellular distribution of 99mTc-DMSA (dimercapto-
succinic acid) complex in the rat kidney has also been
studied. One hour after intravenous injection of labeled
DMSA, kidney tissue homogenate preparations were
subjected to differential subfractionation to obtain cell
organelles. Radioactivity distribution in relation to total
radioactivity of kidney homogenate obtained in five re-
peated experiments was similar to our results [27, 28].Conclusions
In conclusion, the mechanisms involved in the cellular
uptake of 99mTc in bone marrow cells are not known,
but the fact that the activity is distinctly localized in
unique compartments indicates some specificity and not
just a general distribution among structures.
Molecular imaging is undergoing constant change and
is rapidly expanding. It spans all current life sciences
and is being used at the frontiers of modern research.
For the clinical radiologist, the future will bring applica-
tions of molecular imaging techniques into the standard
diagnostic workflow.
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